Smash technology
Smash technology
Humanized PD-1/PD-L1 mouse and cell line
Front Immunol
PLoS One
Immunology
Through a single genetic modification, the addition of a self-cleaving degron tag to a protein of interest allows its inducible, and reversible, degradation upon treatment.
An inducible Knockdown cell line defines a model in which a specific target of interest can be shut down upon treatment.
We use SMASh technology to generate drug inducible protein degradation models. Through a single genetic modification, the addition of a self-cleaving degron tag to a protein of interest allows its inducible, and reversible, degradation upon treatment (further reading).
genOway has an exclusive license for the use of the patented SMASh technology. (See press release)
→ Risks can be strongly minimized by applying in-depth bio-informatic, genetic, and bibliographic analyses
→ An alternative model is a functional Knockout by introducing a point mutation to produce an inactive protein
Immune checkpoint PD-L1 has been identified as a therapeutic target in immuno-oncology and different treatments have been successfully developed to target this protein in oncology.
We developed mouse tumor MC38 cells invalidated for mouse Pd-l1 and overexpressing a SMASh-tagged form of human PD-L1 to reversibly shut down its expression in these cells, thus obtaining cells entirely devoid of PD-L1 upon drug treatment.
Two cell lines developed:
For academic research:
For bio-pharmaceutical research & development:
Human PD-L1 expression was analyzed by flow cytometry. MC38 parental line was used as a negative control. Human colon carcinoma cell line RKO was used as a positive control. Both tagged cell lines express detectable levels of human PD-L1. Note that the position of the SMASh-tag can impact the targeted protein’s level of expression, as MC38-hPD-L1-SMASh cells express higher levels of human PD-L1 than MC38-SMASh-hPD-L1.
Smash technology
Smash technology
Humanized PD-1/PD-L1 mouse and cell line
Front Immunol
PLoS One
Immunology
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate